Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Mitchel L. Zoler, PhD

Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler

News

Experts elevate new drugs for diabetic kidney disease

Author:
Mitchel L. Zoler, PhD
Publish date: June 17, 2022

A consensus statement from the ADA and KDIGO recommends more aggressive combined use of several newer, and costly, drug classes to slow...

  • Read More

News

SGLT2 inhibitors cut AFib risk in real-word analysis

Author:
Mitchel L. Zoler, PhD
Publish date: June 13, 2022

Observational data add to a growing link between SGLT2 inhibitor treatment and atrial fibrillation prevention in people with type 2 diabetes.

  • Read More

News

Antidiabetes drug costs keep patients away

Author:
Mitchel L. Zoler, PhD
Publish date: June 6, 2022

Patients with diabetes and high med co-pays had worse fill rates, but even with low copays uptake of effective but expensive antidiabetes drugs...

  • Read More

News

Tirzepatide powers ‘unprecedented’ weight loss in SURMOUNT-1

Author:
Mitchel L. Zoler, PhD
Publish date: June 5, 2022

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the...

  • Read More

News

ADA prioritizes heart failure in patients with diabetes

Author:
Mitchel L. Zoler, PhD
Publish date: June 1, 2022

Patients with diabetes should have annual screening for biomarkers of early-stage heart failure, and treatment should prioritize an SGLT2...

  • Read More

News

Newly approved tirzepatide’s retail price announced

Author:
Mitchel L. Zoler, PhD
Publish date: May 24, 2022

The recently approved twincretin will carry a U.S. retail price similar to one of its main competitors, semaglutide, but patient discounts will be...

  • Read More

News

Tirzepatide (Mounjaro) approved for type 2 diabetes

Author:
Mitchel L. Zoler, PhD
Publish date: May 16, 2022

Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also...

  • Read More

News

Combo of SGLT2 inhibitor + GLP-1 RA boosts diabetes survival

Author:
Mitchel L. Zoler, PhD
Publish date: April 14, 2022

Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class...

  • Read More

News

Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients

Author:
Mitchel L. Zoler, PhD
Publish date: April 13, 2022

Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE...

  • Read More

News

Flu vaccines cut seasonal death in heart failure patients

Author:
Mitchel L. Zoler, PhD
Publish date: April 5, 2022

Annual influenza vaccines significantly cut death during serial flu seasons in patients with heart failure in...

  • Read More

News

Mavacamten controlled hypertrophic cardiomyopathy for over 1 year

Author:
Mitchel L. Zoler, PhD
Publish date: April 3, 2022

Open-label mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy for a median 62 weeks...

  • Read More

News

SCORED: Sotagliflozin shows robust MACE benefit

Author:
Mitchel L. Zoler, PhD
Publish date: April 2, 2022

Trial results in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the...

  • Read More

News

FDA okays semaglutide higher dose, 2 mg/week, for type 2 diabetes

Author:
Mitchel L. Zoler, PhD
Publish date: March 29, 2022

The 2-mg weekly dose is associated with greater A1c reduction and more weight loss.

  • Read More

News

Empagliflozin scores topline win in EMPA-KIDNEY trial

Author:
Mitchel L. Zoler, PhD
Publish date: March 18, 2022

Researchers stopped the 6,600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial...

  • Read More

News

Finerenone + SGLT2 inhibitor of benefit in diabetes with CKD?

Author:
Mitchel L. Zoler, PhD
Publish date: March 4, 2022

Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors...

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2022 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close